C4 Therapeutics Inc. (CCCC)
CCCC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/0001628280-26-012000-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CCCC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001662579 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $35.9M |
| Net income | -$105.0M |
| Operating income | -$115.2M |
| Net margin | -292.1% |
| Operating margin | -320.5% |
| Revenue growth | +1.0% |
| Cash | $74.6M |
| Total assets | $359.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $32.4M cash; operating cash flow -$19.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 131,317,488 (2026-10-30); 96,914,418 a year earlier; 49,281,046 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $22K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $8.5M | -$21.8M | -$26.0M | $32.4M | No debt tags | $32.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $6.6M | -$23.6M | -$1.6M | $78.6M | No debt tags | $35.0M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $6.2M | -$25.1M | -$29.9M | $61.3M | No debt tags | $34.9M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $11.0M | -$20.5M | -$22.1M | $74.6M | No debt tags | $35.9M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $11.2M | -$32.2M | -$31.2M | $58.8M | No debt tags | $30.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $6.5M | -$26.0M | -$12.1M | $78.2M | No debt tags | $34.2M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $7.2M | -$26.3M | -$33.3M | $51.3M | No debt tags | $39.8M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $5.2M | -$34.6M | -$17.9M | $55.5M | No debt tags | $35.6M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 552 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.0% |
| 1 month | -0.7% |
| 3 months | -32.4% |
| Year to date | +44.5% |
| 1 year | +12.7% |
| From 52-week high | -40.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALEC | Alector Inc. | $2.57 | +1.18% | $382.6M |
| PROK | ProKidney Corp. | $1.04 | -0.48% | $314.5M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.14 | -2.56% | $303.6M |
| KYTX | Kyverna Therapeutics Inc. | $4.76 | -5.74% | $300.9M |
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier